Benralizumab for eosinophilic granulomatosis with polyangiitis.
Adrien CottuMatthieu GrohCharlene DesaintjeanSylvain Marchand-AdamLoïc GuillevinXavier PuechalStacy BeaumesnilEstibaliz LazaroMaxime SamsonCamille TailleCécile-Audrey DurelElizabeth DiotSarah NicolasLaurent GuilleminaultMikael EbboPascal CathebrasClairelyne DupinHalil YildizNabil BelfekiGrégory PugnetPierre ChauvinStephane JouneauFrancois LifermannJean-Philippe MartellosioVincent CottinBenjamin Terriernull nullPublished in: Annals of the rheumatic diseases (2023)
Benralizumab appears to be an effective treatment for refractory asthma or ENT manifestations in EGPA and allows GC-sparing. However, its efficacy was lower after prior failure of mepolizumab.